New drug duo targets hard-to-treat cancers in early trial
NCT ID NCT06938880
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two experimental drugs, ZGGS18 and ZG005, in people with advanced solid tumors (cervical, liver, neuroendocrine, or lung cancer) that no longer respond to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors. About 60 adults aged 18-75 will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can your own immune cells beat advanced cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Could a vaccine help fight Hard-to-Treat cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer